Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 23

1.

A phase I study of an oral simulated FOLFOX with high dose capecitabine.

Mulkerin D, LoConte NK, Holen KD, Thomas JP, Alberti D, Marnocha R, Kolesar J, Eickhoff J, Oliver K, Feierabend C, Wilding G.

Invest New Drugs. 2009 Oct;27(5):461-8. doi: 10.1007/s10637-008-9210-8. Epub 2009 Jan 8.

PMID:
19129971
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials.

Arkenau HT, Arnold D, Cassidy J, Diaz-Rubio E, Douillard JY, Hochster H, Martoni A, Grothey A, Hinke A, Schmiegel W, Schmoll HJ, Porschen R.

J Clin Oncol. 2008 Dec 20;26(36):5910-7. doi: 10.1200/JCO.2008.16.7759. Epub 2008 Nov 17. Erratum in: J Clin Oncol. 2009 Dec 1;27(34):5859.

PMID:
19018087
[PubMed - indexed for MEDLINE]
Free Article
3.

Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor.

Autier J, Escudier B, Wechsler J, Spatz A, Robert C.

Arch Dermatol. 2008 Jul;144(7):886-92. doi: 10.1001/archderm.144.7.886.

PMID:
18645140
[PubMed - indexed for MEDLINE]
4.

Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study.

Hochster HS, Hart LL, Ramanathan RK, Childs BH, Hainsworth JD, Cohn AL, Wong L, Fehrenbacher L, Abubakr Y, Saif MW, Schwartzberg L, Hedrick E.

J Clin Oncol. 2008 Jul 20;26(21):3523-9. doi: 10.1200/JCO.2007.15.4138. Erratum in: J Clin Oncol. 2008 Oct 1;26(28): 4697.

PMID:
18640933
[PubMed - indexed for MEDLINE]
5.

Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib.

Lacouture ME, Reilly LM, Gerami P, Guitart J.

Ann Oncol. 2008 Nov;19(11):1955-61. doi: 10.1093/annonc/mdn389. Epub 2008 Jun 10.

PMID:
18550575
[PubMed - indexed for MEDLINE]
Free Article
6.

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Cassidy J.

J Clin Oncol. 2008 Apr 20;26(12):2013-9. doi: 10.1200/JCO.2007.14.9930. Erratum in: J Clin Oncol. 2008 Jun;26(18):3110. J Clin Oncol. 2009 Feb 1;27(4):653.

PMID:
18421054
[PubMed - indexed for MEDLINE]
Free Article
7.

Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.

Cassidy J, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Saltz L.

J Clin Oncol. 2008 Apr 20;26(12):2006-12. doi: 10.1200/JCO.2007.14.9898.

PMID:
18421053
[PubMed - indexed for MEDLINE]
Free Article
8.

Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group.

Porschen R, Arkenau HT, Kubicka S, Greil R, Seufferlein T, Freier W, Kretzschmar A, Graeven U, Grothey A, Hinke A, Schmiegel W, Schmoll HJ; AIO Colorectal Study Group.

J Clin Oncol. 2007 Sep 20;25(27):4217-23. Epub 2007 Jun 4.

PMID:
17548840
[PubMed - indexed for MEDLINE]
Free Article
9.

Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial.

Díaz-Rubio E, Tabernero J, Gómez-España A, Massutí B, Sastre J, Chaves M, Abad A, Carrato A, Queralt B, Reina JJ, Maurel J, González-Flores E, Aparicio J, Rivera F, Losa F, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumors Trial.

J Clin Oncol. 2007 Sep 20;25(27):4224-30. Epub 2007 Jun 4.

PMID:
17548839
[PubMed - indexed for MEDLINE]
Free Article
10.

Survival after hepatic resection in metastatic colorectal cancer: a population-based study.

Cummings LC, Payes JD, Cooper GS.

Cancer. 2007 Feb 15;109(4):718-26.

PMID:
17238180
[PubMed - indexed for MEDLINE]
Free Article
11.

Capecitabine plus oxaliplatin (xelox) versus protracted 5-fluorouracil venous infusion plus oxaliplatin (pvifox) as first-line treatment in advanced colorectal cancer: a GOAM phase II randomised study (FOCA trial).

Martoni AA, Pinto C, Di Fabio F, Lelli G, Rojas Llimpe FL, Gentile AL, Mutri V, Ballardini P, Giaquinta S, Piana E.

Eur J Cancer. 2006 Dec;42(18):3161-8. Epub 2006 Nov 13.

PMID:
17098421
[PubMed - indexed for MEDLINE]
12.

Management of hand-foot syndrome induced by capecitabine.

Gressett SM, Stanford BL, Hardwicke F.

J Oncol Pharm Pract. 2006 Sep;12(3):131-41. Review.

PMID:
17022868
[PubMed - indexed for MEDLINE]
13.

XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer.

Feliu J, Salud A, Escudero P, Lopez-Gómez L, Bolaños M, Galán A, Vicent JM, Yubero A, Losa F, De Castro J, de Mon MA, Casado E, González-Barón M.

Br J Cancer. 2006 Apr 10;94(7):969-75.

PMID:
16552438
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer.

Cassidy J, Tabernero J, Twelves C, Brunet R, Butts C, Conroy T, Debraud F, Figer A, Grossmann J, Sawada N, Schöffski P, Sobrero A, Van Cutsem E, Díaz-Rubio E.

J Clin Oncol. 2004 Jun 1;22(11):2084-91.

PMID:
15169795
[PubMed - indexed for MEDLINE]
Free Article
15.

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.

Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, de Gramont A.

J Clin Oncol. 2004 Jan 15;22(2):229-37. Epub 2003 Dec 2.

PMID:
14657227
[PubMed - indexed for MEDLINE]
Free Article
16.

Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly.

Aparicio T, Desramé J, Lecomte T, Mitry E, Belloc J, Etienney I, Montembault S, Vayre L, Locher C, Ezenfis J, Artru P, Mabro M, Dominguez S; AGEO.

Br J Cancer. 2003 Oct 20;89(8):1439-44.

PMID:
14562014
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer.

Scheithauer W, Kornek GV, Raderer M, Schüll B, Schmid K, Kovats E, Schneeweiss B, Lang F, Lenauer A, Depisch D.

J Clin Oncol. 2003 Apr 1;21(7):1307-12.

PMID:
12663719
[PubMed - indexed for MEDLINE]
Free Article
18.

Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.

Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, Bugat R, Findlay M, Frings S, Jahn M, McKendrick J, Osterwalder B, Perez-Manga G, Rosso R, Rougier P, Schmiegel WH, Seitz JF, Thompson P, Vieitez JM, Weitzel C, Harper P; Xeloda Colorectal Cancer Study Group.

J Clin Oncol. 2001 Nov 1;19(21):4097-106.

PMID:
11689577
[PubMed - indexed for MEDLINE]
Free Article
19.

Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients.

Schüller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L, Utoh M, Mori K, Weidekamm E, Reigner B.

Cancer Chemother Pharmacol. 2000;45(4):291-7.

PMID:
10755317
[PubMed - indexed for MEDLINE]
20.

Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study.

Van Cutsem E, Findlay M, Osterwalder B, Kocha W, Dalley D, Pazdur R, Cassidy J, Dirix L, Twelves C, Allman D, Seitz JF, Schölmerich J, Burger HU, Verweij J.

J Clin Oncol. 2000 Mar;18(6):1337-45.

PMID:
10715306
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk